Opioid-class REMS unlikely to halt abuse; U.S. trade office IDs Brazil, China, India among counterfeit hot spots;

> Opioid REMS implementation costs will be passed along to consumers and third-party payers, despite their "unlikely" ability to reduce or mitigate opioid abuse. Article

> The Office of the United States Trade Representative cites Brazil, China, India, Indonesia and Russia as areas of concern for the proliferation of counterfeit drugs. Article

> Catalent has named Barry Russell president of its commercial packaging group. Release

> Big-three drug distributor McKesson's yearly outlook beat Wall Street's estimate. Item

> Increasing challenges balanced by sound fundamentals and healthy growth prospects will yield stable credit risk profiles for Indian pharma companies in the international markets, says CRISIL Ratings. Article

Suggested Articles

The FDA has found issues with the testing practices of a U.S. generics maker that had specific problems with ADHD and weight-loss drugs.

A warning letter says Chinese API maker Yibin Lihao Bio-technical was found lying to the FDA about manufacturing unapproved heparin.

It took four tries over four years, but Perrigo has finally gotten FDA approval of its generic of Teva’s tricky-to-make ProAir HFA asthma inhaler.